PMID- 16964782
OWN - NLM
STAT- MEDLINE
DCOM- 20070222
LR  - 20070320
IS  - 1027-3719 (Print)
IS  - 1027-3719 (Linking)
VI  - 10
IP  - 9
DP  - 2006 Sep
TI  - Tuberculosis immune reconstitution inflammatory syndrome in countries with 
      limited resources.
PG  - 946-53
AB  - Mycobacterium tuberculosis infection accounts for probably one third of human 
      immunodeficiency virus (HIV) related immune reconstitution inflammatory syndrome 
      (IRIS) events, particularly in developing countries where HIV and tuberculosis 
      (TB) co-infection is very common. Small cohort studies of HIV-positive patients 
      with active TB treated with antiretroviral therapy (ART) suggest an incidence of 
      TB IRIS varying between 11% and 45%. Risk factors for TB IRIS that have been 
      suggested in certain studies but not in others include: starting ART within 6 
      weeks of starting TB treatment; extra-pulmonary or disseminated disease; a low 
      CD4+ lymphocyte count and a high viral load at the start of ART; and a good 
      immunological and virological response during highly active antiretroviral 
      therapy (HAART). It is important to agree on a clinical case definition of TB 
      IRIS that could be used in resource-limited settings. Such a case definition 
      could be used to determine the exact incidence and consequences of TB IRIS and 
      would be valuable worldwide in clinical trials that are needed to answer 
      questions on how this phenomenon could be prevented and treated.
FAU - Colebunders, R
AU  - Colebunders R
AD  - Infectious Disease Institute, Faculty of Medicine, Makerere University, Kampala, 
      Uganda. bcoleb@itg.be
FAU - John, L
AU  - John L
FAU - Huyst, V
AU  - Huyst V
FAU - Kambugu, A
AU  - Kambugu A
FAU - Scano, F
AU  - Scano F
FAU - Lynen, L
AU  - Lynen L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal 
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - Antiretroviral Therapy, Highly Active
MH  - Antitubercular Agents/therapeutic use
MH  - HIV Infections/drug therapy/*immunology
MH  - Humans
MH  - Inflammation/*immunology
MH  - Syndrome
MH  - Tuberculosis, Pulmonary/drug therapy/*immunology
RF  - 52
EDAT- 2006/09/13 09:00
MHDA- 2007/02/23 09:00
CRDT- 2006/09/13 09:00
PHST- 2006/09/13 09:00 [pubmed]
PHST- 2007/02/23 09:00 [medline]
PHST- 2006/09/13 09:00 [entrez]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2006 Sep;10(9):946-53.